RPRX SEC Filings

Royalty Pharma Quarterly Report for Q3 Ended Sep 30, 2026

Royalty Pharma 8-K Report, Financial Results (Nov 4, 2026)

Royalty Pharma 8-K Report, Financial Results (Aug 5, 2026)

Royalty Pharma plc (Nasdaq: RPRX) reported second quarter 2026 results on August 5, 2026, via a press release furnished as Exhibit 99.1. Royalty Receipts grew 14% to $768 million, driven by Tremfya, Voranigo, Imdelltra and Evrysdi, partly offset by declines from Promacta (U.S. generic competition) and Imbruvica. Portfolio Receipts rose 6% to $773 million, though milestones and other contractual receipts fell to $5 million from $56 million, reflecting a one-time distribution in the prior-year period. Net cash provided by operating activities was $728 million versus $364 million a year earlier, and Adjusted EBITDA (non-GAAP) was $736 million, up 16%. Management raised full-year 2026 Portfolio Receipts guidance to $3,400 million to $3,500 million from $3,325 million to $3,450 million, implying expected Royalty Receipts growth of 7% to 10%. Guidance excludes transactions announced after the release date. Interest paid is expected to be $350 million to $360 million, and the $380 million term loan was repaid in July 2026. As of June 30, 2026, the company held cash and cash equivalents of $812 million and total debt with principal value of $9.2 billion. Capital Deployment was $349 million in the quarter, and the company disclosed new transactions of up to $1.7 billion as of August 4, 2026, including a July 2026 acquisition of a portion of the royalty on AstraZeneca's cliramitug for up to $425 million ($125 million upfront).

Royalty Pharma Quarterly Report for Q2 Ended Jun 30, 2026

Royalty Pharma plc (RPRX) reported second-quarter 2026 consolidated net income of $81.5 million, down from $92.6 million a year earlier, while net income attributable to Royalty Pharma plc fell to $17.9 million from $32.2 million. For the first six months of 2026, net income attributable to Royalty Pharma plc rose to $312.6 million from $271.5 million, and diluted EPS was $0.71 versus $0.63. Total income and other revenues grew to $674.1 million in the quarter from $578.7 million, driven by higher income from financial royalty assets, which was $638.0 million versus $550.4 million. Operating income declined to $133.1 million from $209.8 million, mainly because of a $268.2 million provision for changes in expected cash flows, largely tied to Adstiladrin, compared with a $203.9 million provision benefit in the prior-year quarter. Cash generation remained strong. Net cash provided by operating activities for the first six months of 2026 was $1.45 billion, up from $960.1 million, and Portfolio Cash Flow was $1.46 billion. The company invested $876.7 million in royalties, milestones and other contractual receipts in the first half. Cash and cash equivalents were $812.0 million at June 30, 2026. Total debt principal was $9.2 billion, and the company entered a new $1.8 billion unsecured revolving credit facility on May 22, 2026, which matures in 2031. Share-based compensation rose sharply after the May 2025 Internalization, reaching $107.4 million in the quarter. Subsequent to quarter end, the company acquired a royalty interest in AstraZeneca's cliramitug from Neurimmune AG for up to $425 million, including a $125 million upfront payment. The filing also notes an ongoing dispute with Vertex over royalties on Alyftrek, under which the company has not received the full royalty amounts it believes it is contractually entitled to.

Royalty Pharma 8-K Report, Shareholder Vote Results (Jun 4, 2026)

Royalty Pharma plc held its 2026 Annual General Meeting of Shareholders on June 4, 2026. Shareholders present or represented by proxy held 508,180,103 Class A and Class B ordinary shares, voting as a single class, which the filing states represented 88.08% of the combined voting power entitled to vote and constituted a quorum. The filing reports the results of ten proposals, each described in the company's definitive proxy statement filed April 10, 2026. All nine director nominees were elected to serve until the 2027 Annual General Meeting. Each received more votes For than Against, though the against votes ranged from 128,998 for Elizabeth Weatherman to 54,472,087 for Vlad Coric, M.D. Shareholders also approved the non-binding advisory say-on-pay proposal (476,044,602 For, 11,067,486 Against, 747,086 Abstain), the U.K. Annual Report and Accounts, the U.K. directors' remuneration report, and the re-appointment of Ernst & Young as U.K. statutory auditor. Ernst & Young LLP was also ratified as the independent registered public accounting firm, with 506,307,829 votes For and 832,217 Against. Shareholders approved the terms of share repurchase agreements and counterparties (474,475,427 For, 12,499,628 Against), and authorized the Board to allot shares (469,111,384 For, 18,568,396 Against). The authority to allot shares without pre-emption rights drew the most opposition of the non-director items, at 445,653,078 For and 42,016,406 Against. The filing was signed by Arthur McGivern, EVP, General Counsel & Investments.

Royalty Pharma 8-K Report, Material Agreement (May 28, 2026)

On May 22, 2026, Royalty Pharma plc, Royalty Pharma Holdings Ltd (RPH), and Royalty Pharma Manager, LLC (RPM) entered into a new Revolving Credit Agreement with Bank of America, N.A., as Administrative Agent, and the other lenders party to it. The Company is the borrower, and RPH and RPM are guarantors. The agreement refinanced and replaced in its entirety the Revolving Credit Agreement dated September 15, 2021. All obligations under that existing facility were repaid and its commitments were terminated at the effective date of the new agreement. The new facility is an unsecured revolving credit line of $1.8 billion. Borrowings bear interest at either a base rate or a SOFR-based or alternative currency rate, in each case plus an applicable margin, and the unused portion carries a commitment fee set by a pricing grid. The facility matures on May 22, 2031. The Credit Agreement includes financial covenants requiring a consolidated leverage ratio of funded debt to Adjusted EBITDA at or below 4.00 to 1.00 (or 4.50 to 1.00 following a qualifying material acquisition), a consolidated portfolio cash flow ratio at or below 5.00 to 1.00 (or 5.50 to 1.00 following a qualifying material acquisition), and a consolidated coverage ratio of Adjusted EBITDA to consolidated interest expense at or above 2.50 to 1.00. It also includes customary restrictions on non-obligor indebtedness, liens, and certain merger or fundamental change transactions. The filing is a refinancing and replacement of an existing facility rather than a new source of capital described in the filing itself. The full terms are set out in Exhibit 10.1, the Revolving Credit Agreement, which is incorporated by reference.

Royalty Pharma 8-K Report, Financial Results (May 6, 2026)

Royalty Pharma plc (Nasdaq: RPRX) reported first quarter 2026 results on May 6, 2026, furnishing a press release as Exhibit 99.1 under Item 2.02. Portfolio Receipts rose 10% to $925 million, driven by Royalty Receipts, which grew 13% to $887 million on strength from Tremfya, Voranigo and Evrysdi, partly offset by a decline from Promacta due to U.S. generic competition. Net cash provided by operating activities was $718 million, and Adjusted EBITDA (non-GAAP) was $889 million, up from $738 million. Portfolio Cash Flow (non-GAAP) was $722 million. The company raised its full-year 2026 Portfolio Receipts guidance to $3,325 million to $3,450 million, from $3,275 million to $3,425 million previously, excluding future transactions. The guidance implies expected Royalty Receipts growth of 4% to 8%. Interest paid is projected at $350 million to $360 million for 2026, with approximately $175 million expected in the third quarter. Deployment activity included three royalty acquisitions announced for $1.25 billion, including a Ziihera royalty bought from Zymeworks for $250 million, and R&D co-funding agreements with Johnson & Johnson (JNJ-4804, $500 million over two years) and Teva (TEV-'408, up to $500 million). Capital Deployment was $528 million in the quarter. The company also recorded $69 million of non-cash impairment charges related to Tazverik. As of March 31, 2026, cash was $586 million and total debt principal was $9.2 billion.

Royalty Pharma Quarterly Report for Q1 Ended Mar 31, 2026

Royalty Pharma plc (RPRX) reported first-quarter 2026 consolidated net income of $468.3 million, up from $434.4 million in the prior-year period, and net income attributable to Royalty Pharma plc of $294.7 million versus $239.3 million. Diluted EPS was $0.67 compared with $0.55. Total income and other revenues rose to $630.6 million from $568.2 million, led by income from financial royalty assets of $595.0 million. Results were partly offset by a $69.4 million non-cash financial royalty asset impairment related to Tazverik, following its voluntary withdrawal, and by general and administrative expenses that rose to $159.5 million, driven by share-based compensation of $122.3 million tied to the Internalization. The filing also recorded a $197.5 million provision income from changes in expected cash flows and credit losses. Cash flow from operations was $718.2 million, up from $596.1 million. Portfolio Receipts were $925.4 million versus $839.3 million, and Portfolio Cash Flow was $722.1 million versus $610.8 million (non-GAAP). The company invested $527.9 million in royalties, milestones and other contractual receipts, including acquisitions of financial royalty assets of $452.4 million in the cash flow statement. It repurchased 1.1 million Class A shares for about $50.1 million, leaving approximately $1.7 billion under the repurchase program, and paid a $0.235 per share quarterly dividend totaling $104.5 million. Total debt principal was $9.2 billion at March 31, 2026, including a $380 million term loan maturing July 31, 2026. Cash and cash equivalents were $586.4 million. The filing notes that Vertex's Alyftrek royalty payments are in a dispute resolution process, and that Revolution Medicines' second $250 million royalty tranche was funded on May 4, 2026, following positive Phase 3 results.

Royalty Pharma 8-K Report, Regulation FD Disclosure (Apr 13, 2026)

Royalty Pharma plc (RPRX) filed this Form 8-K under Item 7.01 (Regulation FD Disclosure) to disclose that Revolution Medicines, Inc. announced positive Phase 3 results from the RASolute 302 trial of daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The trial met all primary and key secondary endpoints, including progression-free survival and overall survival. Revolution Medicines intends to submit the data to global regulatory authorities, including the FDA, as part of a future New Drug Application under a Commissioner's National Priority Voucher. The filing describes the $2 billion funding agreement announced in June 2025, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million. Royalty Pharma funded $250 million upfront, and the announcement triggered an additional $250 million tranche. Following this second tranche, Royalty Pharma's total tiered royalty on daraxonrasib sales (and zoldonrasib if approved in an overlapping indication) is 4.55% on sales from $0 to $2 billion, 2.50% on sales from $2 billion to $4 billion, and 1.00% on sales from $4 billion to $8 billion. The filing also describes up to $750 million in additional synthetic royalty funding at Revolution Medicines' option upon certain regulatory, commercial and clinical milestones, including the next $250 million on FDA approval in metastatic PDAC. If fully drawn, the royalty rates would increase to 7.80%, 4.55% and 2.40% across the same sales bands. Separately, Royalty Pharma is providing a senior secured term loan of up to $750 million in three tranches; the first $250 million must be drawn following FDA approval of daraxonrasib for metastatic PDAC, and the two remaining $250 million tranches are at Revolution Medicines' option based on trailing four-quarter net sales milestones.

Royalty Pharma 8-K Report, Financial Results (Feb 11, 2026)

Royalty Pharma plc (Nasdaq: RPRX) reported fourth-quarter and full-year 2025 results in a press release furnished as Exhibit 99.1 to this Form 8-K. Portfolio Receipts were $874 million in Q4 2025, up 18% from $742 million, and $3,254 million for FY 2025, up 16% from $2,801 million. Net cash provided by operating activities was $827 million in Q4 2025 and $2,490 million for FY 2025, down 10% for the full year. Adjusted EBITDA (non-GAAP) was $2,966 million for FY 2025, up 16%, and Portfolio Cash Flow (non-GAAP) was $2,724 million, up 11%. The company deployed $2.6 billion of capital in 2025, including $1.2 billion of share repurchases (37 million Class A shares) and a record amount of capital returned to shareholders. It also highlighted the successful internalization of its external manager, which extinguished the management fee after May 16, 2025. Management guided 2026 Portfolio Receipts to $3,275 million to $3,425 million, excluding future transactions, with Royalty Receipts growth of 3% to 8% and interest paid of $350 million to $360 million. The quarterly dividend was raised 7% to $0.235 per share in Q1 2026. At year-end 2025 the company had cash and cash equivalents of $619 million and total debt with principal value of $9.2 billion. Balance sheet data show long-term debt, net of current portion, rising to $8,571 million from $6,615 million a year earlier. Investors will watch 2026 catalysts the release names, including pivotal study results for daraxonrasib, pelacarsen and litifilimab, along with new royalty transactions such as the up-to-$500 million Teva TEV-'408 funding agreement announced in January 2026.

Royalty Pharma Annual Report, Year Ended Dec 31, 2025

Royalty Pharma plc (RPRX) reported 2025 Portfolio Receipts of $3.3 billion ($3,254,361 thousand), up from $2.80 billion in 2024, with Royalty Receipts of $3.13 billion. Total income and other revenues rose 5.1% to $2.38 billion, but consolidated net income was roughly flat at $1.32 billion and net income attributable to Royalty Pharma plc fell 10.2% to $770.9 million. The decline was driven by a $1.03 billion swing in the provision for changes in expected cash flows (a $295.8 million provision income in 2025 versus $732.5 million expense in 2024), a $336.8 million increase in G&A expenses (largely share-based compensation following the May 2025 Internalization), and $450.0 million of R&D funding expense, partly offset by a $267.1 million increase in operating income. The company deployed $2.6 billion of cash on royalties, milestones and other contractual receipts in 2025, returned $511.9 million through dividends and distributions and repurchased $1.2 billion of Class A shares, and ended the year with $9.2 billion of principal borrowings against $618.7 million of cash. Net cash from operating activities was $2.49 billion, down from $2.77 billion. The filing notes ongoing dispute resolution with Vertex over Alyftrek royalty receipts, and states that Vertex accounted for 35% of 2025 total income and other revenues. For investors, the key items are the strong growth in cash receipts and the large non-cash swings in GAAP income from the effective interest accounting model, alongside higher leverage, higher interest expense ($307.7 million, up 36.4%) and the increased compensation cost of the Internalization.

Royalty Pharma 8-K Report, Executive Changes (Dec 22, 2025)

Royalty Pharma plc (RPRX) filed this Current Report on Form 8-K dated December 22, 2025 under Item 5.02, disclosing a leadership transition in its legal function. George W. Lloyd, age 66, informed the company on December 20, 2025 of his decision to step down as Executive Vice President and Chief Legal Officer effective December 31, 2025. He will remain with the company as a senior advisor. Arthur R. McGivern, age 50, Executive Vice President and General Counsel, will assume Mr. Lloyd's responsibilities effective January 1, 2026. Mr. McGivern joined the company in October 2022 and previously was a partner at Goodwin Procter LLP. The filing also states that Mr. Lloyd and the company have agreed to terminate his Executive Offer Letter dated May 16, 2025, effective December 31, 2025, and that he will enter into the company's standard form employee offer letter effective January 1, 2026. The filing contains no financial results or compensation figures.

Royalty Pharma 8-K Report, Regulation FD Disclosure (Dec 22, 2025)

Royalty Pharma plc reported in a Form 8-K filed December 22, 2025 (Item 7.01, Regulation FD Disclosure) that the U.S. Food and Drug Administration approved a New Drug Application for MYQORZO (aficamten), announced by Cytokinetics, Incorporated on December 19, 2025. MYQORZO is a cardiac myosin inhibitor for adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), intended to improve functional capacity and symptoms. Under funding agreements with Cytokinetics dated January 2022 and May 2024, Royalty Pharma is entitled to a royalty of 4.5% on MYQORZO sales up to $5 billion, decreasing to 1% on sales above $5 billion. The company also provided Cytokinetics long-term capital of up to $225 million in 2022, all of which has been drawn, and additional launch capital of up to $225 million in 2024, of which $50 million has been drawn. Based on amounts drawn to date, Royalty Pharma will receive $523 million in quarterly repayments over 10 years (1.9x the total amount drawn), of which $20 million had been repaid through September 30, 2025. Following the approval, Cytokinetics is eligible to draw an additional $175 million within the next 12 months, which would also be repaid at 1.9x the amount drawn over 10 years in quarterly installments.

Royalty Pharma 8-K Report, Financial Results (Nov 5, 2025)

Royalty Pharma plc (Nasdaq: RPRX) reported third quarter 2025 results on November 5, 2025, in a press release furnished as Exhibit 99.1 to this Form 8-K. Portfolio Receipts grew 11% to $814 million, Royalty Receipts grew 11% to $811 million, and net cash provided by operating activities was $703 million. Adjusted EBITDA (non-GAAP) was $779 million and Portfolio Cash Flow (non-GAAP) was $657 million for the quarter. The company raised its full-year 2025 Portfolio Receipts guidance to $3,200 million to $3,250 million, from the previous $3,050 million to $3,150 million, representing expected growth of 14% to 16% versus the previously expected 9% to 12%. The guidance excludes contributions from transactions announced after the release date. Management also expects 2025 interest paid of approximately $275 million and 2026 interest paid of approximately $350 to $360 million. Capital deployment was $1.0 billion in the third quarter and $1.7 billion for the first nine months of 2025, and management cited new transactions of up to $3.8 billion announced during 2025. The company issued $2.0 billion of senior unsecured notes in September 2025 and repaid $1.0 billion of notes at maturity in August 2025. Share repurchases totaled $152 million in the quarter and $1.2 billion year to date, and cash and cash equivalents were $939 million as of September 30, 2025.

Royalty Pharma Quarterly Report for Q3 Ended Sep 30, 2025

Royalty Pharma plc (RPRX) reported third-quarter 2025 consolidated net income of $444.2 million, compared with $806.4 million in the third quarter of 2024, and net income attributable to Royalty Pharma plc of $288.2 million versus $544.0 million. Basic EPS was $0.67 versus $1.22. The decline was driven mainly by a swing in the provision for changes in expected cash flows (a $12.1 million expense in Q3 2025 versus $227.6 million of income in Q3 2024), higher share-based compensation of $73.4 million following the May 16, 2025 Internalization, and R&D funding expense of $50.5 million. Income from financial royalty assets rose 8.6% to $578.8 million, and Portfolio Receipts rose 10.8% to $813.6 million for the quarter. For the first nine months, total income and other revenues were $1.76 billion and net income attributable to Royalty Pharma plc was $556.7 million. The company completed the Internalization of its former external manager, recording goodwill of $924.6 million and a $379.9 million... [note: term loan of $380 million assumed]. Share-based compensation now includes $76.5 million related to RP Holdings Class E Interests and $84.7 million related to Employee EPAs for the nine months, with approximately $678.9 million and $71.5 million of unrecognized expense, respectively. Total debt principal was $9.18 billion at September 30, 2025, up from $7.8 billion at year-end 2024, after issuing $2.0 billion of senior unsecured notes in September 2025 and repaying $1.0 billion of notes. Capital deployment remained active: the company invested $1.7 billion in royalties, milestones and other contractual receipts in the first nine months of 2025, including the $885 million BeOne Imdelltra royalty and up to $2 billion of Revolution Medicines funding. Repurchases totaled 35.4 million Class A shares for about $1.2 billion in the first nine months, with approximately $1.9 billion remaining under the authorization. A subsequent event was the November 2025 acquisition of an Amvuttra royalty from Blackstone for $310 million. The company also disclosed that Vertex has not paid the full amount of Alyftrek royalties the company believes it is contractually owed, and that it has begun dispute resolution procedures.

Royalty Pharma 8-K Report, Material Agreement (Sep 16, 2025)

On September 16, 2025, Royalty Pharma plc closed its previously announced offering of $2.0 billion in aggregate principal amount of senior notes, consisting of $600 million of 4.450% Senior Notes due 2031, $900 million of 5.200% Senior Notes due 2035, and $500 million of 5.950% Senior Notes due 2055. The Notes were issued under a base indenture dated September 2, 2020, as supplemented by a fourth supplemental indenture dated June 9, 2025 and a fifth supplemental indenture dated September 16, 2025, among the issuer, Royalty Pharma Holdings Ltd, Royalty Pharma Manager, LLC and Wilmington Trust, National Association, as trustee. The Notes are guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC. Interest on all three series is payable semi-annually on March 25 and September 25, beginning March 25, 2026, with maturities of March 25, 2031, September 25, 2035 and September 25, 2055, respectively. The Indenture includes customary covenants, and the issuer must offer to repurchase the Notes upon certain change of control events. The issuer may redeem the Notes at times and prices set out in the Indenture. The filing also reports that on September 2, 2025, the issuer and guarantors entered into an underwriting agreement with representatives of the several underwriters, including BofA Securities, Goldman Sachs, J.P. Morgan, Morgan Stanley and TD Securities, covering the terms of the offering, indemnification and contribution obligations. Investors should note the new debt obligations and their longer maturities as the company's capital structure changes.

Royalty Pharma 8-K Report, Executive Changes (Aug 13, 2025)

Royalty Pharma plc (Nasdaq: RPRX) filed a Form 8-K on August 13, 2025 to report that Henry Fernandez, its Lead Independent Director, is stepping down from the Board of Directors, effective August 13, 2025. The filing states that his decision did not result from any disagreement between the Company and Mr. Fernandez. The Board and executive team extended gratitude for his five years of service on the Board. The Company issued a press release the same day announcing the departure, which is attached as Exhibit 99.1. In that release, Mr. Fernandez is credited with helping the Company achieve milestones including the completion of the internalization, and CEO Pablo Legorreta describes the Company as positioned favorably for continued growth. The release states that the Company intends to name a new Lead Independent Director in the near future. For investors, the filing is primarily a governance update: the loss of a lead independent director and the pending appointment of a successor. The filing does not disclose any financial results, figures, or changes to the Company's business operations.

Royalty Pharma 8-K Report, Financial Results (Aug 6, 2025)

Royalty Pharma plc (Nasdaq: RPRX) reported second quarter 2025 results on August 6, 2025, as furnished in Exhibit 99.1 to this Form 8-K. Portfolio Receipts rose 20% to $727 million, Royalty Receipts grew 11% to $672 million, and net cash provided by operating activities was $364 million, down from $658 million a year earlier. The company raised its full-year 2025 Portfolio Receipts guidance to $3,050 million to $3,150 million from $2,975 million to $3,125 million, and now expects growth of 9% to 12%. Management highlighted the closing in May 2025 of the internalization of its external manager, RP Management, LLC, which made the company an integrated public company. Capital Deployment was $595 million in the quarter, including funding for daraxonrasib under a Revolution Medicines arrangement of up to $2 billion, and the company repurchased $1 billion of Class A ordinary shares in the first half of 2025. Cash and cash equivalents were $632 million and total debt principal was $8.2 billion as of June 30, 2025. The filing also discloses that Royalty Pharma commenced dispute resolution procedures with Vertex because it did not receive the full amount of Royalty Receipts on Alyftrek net sales to which it is contractually entitled. Management noted that an Investor Day is scheduled for September 11th.

Royalty Pharma Quarterly Report for Q2 Ended Jun 30, 2025

Royalty Pharma plc (RPRX) reported a second quarter 2025 10-Q covering the period ended June 30, 2025. Consolidated net income was $90.6 million for the quarter, compared with $194.4 million in the second quarter of 2024, and net income attributable to Royalty Pharma plc was $30.2 million, versus $102.0 million a year earlier. Results were driven by a $300.5 million R&D funding expense (primarily an upfront $250.0 million payment for daraxonrasib royalties), a $92.5 million provision for credit losses on the Revolution Medicines funding commitments, and $45.7 million... more precisely, $91.0 million of quarterly share-based compensation tied largely to the Internalization. Total income and other revenues rose to $578.7 million from $537.3 million, and the company recorded a $203.9 million provision benefit from changes in expected cash flows. The company completed the Internalization on May 16, 2025, acquiring its former external manager, RP Management, LLC. The filing reports goodwill of $924.6 million, a $380 million term loan assumed, and a total purchase price of $565.2 million. Going forward, the company no longer pays Operating and Personnel Payments to the legacy manager, but G&A expenses rose sharply, and share-based compensation for 22.8 million unvested RP Holdings Class E Interests is expected to be recognized over five to nine years. Capital deployment was heavy: the company repurchased 31.2 million Class A shares for about $1.0 billion in the first six months of 2025, leaving roughly $2.0 billion under its authorization. Cash and cash equivalents fell to $631.9 million from $929.0 million at year-end 2024, and total borrowings reached $8.2 billion in principal. Portfolio Receipts rose 19.7% to $727.5 million in the quarter, and Vertex's cystic fibrosis franchise remained the largest revenue contributor at 35% of total income and other revenues. The company also disclosed that Vertex did not remit the full amount of royalties on Alyftrek net sales in the second quarter, and it has started dispute resolution procedures.

Royalty Pharma 8-K Report, Executive Changes (Jul 17, 2025)

Royalty Pharma plc (Nasdaq: RPRX) filed a Form 8-K on July 17, 2025 to report the appointment of two new independent directors to its Board of Directors, Carole Ho and Elizabeth (Bess) Weatherman, effective July 17, 2025. Dr. Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, and Ms. Weatherman is a Special Limited Partner of Warburg Pincus LLC. The Board determined that both meet the applicable independence standards under Nasdaq Global Select Market listing rules and Item 407(a) of Regulation S-K. Each will stand for election for the first time at the Company's 2026 Annual General Meeting and will receive compensation under the Company's Independent Director Compensation Policy, as described in the proxy statement filed April 11, 2025. The filing states that the appointments increase independent board representation to greater than 90%, and the accompanying press release frames them as part of an enhanced corporate governance commitment following the acquisition of the company's external manager. Each director will also enter into a standard deed of indemnity in the form previously approved by the Board. The filing reports no family relationships with executive officers or directors and no arrangements or understandings with other persons regarding the appointments. For investors, the filing is primarily a governance update rather than a financial disclosure. It contains no financial results or guidance. The press release, attached as Exhibit 99.1, provides biographical details and a statement from CEO Pablo Legorreta highlighting the directors' biopharmaceutical and investment experience.

Royalty Pharma 8-K Report, Material Agreement (May 19, 2025)

On May 16, 2025, Royalty Pharma Holdings Ltd. (RPH), a subsidiary of Royalty Pharma plc, completed the previously announced Transaction under the Membership Interests Purchase Agreement dated January 10, 2025 (as amended April 11, 2025) and acquired all equity interests of Royalty Pharma Manager, LLC (f/k/a Royalty Pharma, LLC) from the Sellers. The aggregate consideration consisted of $200,000,000 in cash, less certain 2025 management fee payments received by RP Management and RP LLC from January 1 through May 16, 2025, subject to customary adjustments, plus 24,530,266 non-voting Class E ordinary shares of RPH. RPH also assumed RP Management's $380 million term loan facility. In connection with the closing, RP Management was released as a borrower and guarantor under the existing loan agreement and guaranty dated December 11, 2023, while RPH and RP LLC were joined as borrowers and guarantors under the amended loan agreement with Bank of America, N.A. The filing also reports an amended and restated exchange agreement allowing certain recipients to exchange Class E shares of RPH (after redesignation into Class B shares) for the company's Class A ordinary shares on a one-for-one basis, and amended and restated articles of association for both Royalty Pharma plc and RPH. For management, the filing states that the Named Executive Officers (Pablo Legorreta, Terrance Coyne, Christopher Hite, George Lloyd and Marshall Urist) entered into offer letters providing one year of base salary continuation upon termination without cause or resignation for good reason, subject to a release and continued restrictive covenant compliance. Pablo Legorreta's share consideration vests straight-line over five years, and other RP Management members' shares vest straight-line over ten years beginning in 2024.

Royalty Pharma 8-K Report, Shareholder Vote Results (May 12, 2025)

On May 12, 2025, Royalty Pharma plc held its 2025 Annual General Meeting and Special Meeting of Shareholders, with 493,716,628 Class A and Class B ordinary shares present or represented by proxy, representing 85.96% of the combined voting power entitled to vote and constituting a quorum. Shareholders voted on 15 proposals described in the definitive proxy statement filed April 11, 2025. The most consequential items relate to the "Internalization Proposal" and the related Membership Interest Purchase Agreement, which the filing references in Proposals 1 and 2, along with the non-binding advisory vote on compensation payable to named executive officers in connection with the Transaction (Proposal 3). Several proposals passed with strong support, including the ratification of Ernst & Young LLP as independent registered public accounting firm (493,521,988 for, 116,396 against), the approval of the U.K. statutory accounts for the fiscal year ended December 31, 2023 (493,059,166 for, 98,388 against), and the re-appointment of Ernst & Young Chartered Accountants as U.K. statutory auditor. Nine directors were nominated for election to serve until the 2026 Annual General Meeting. Ted Love, M.D. received the most opposition among nominees, with 31,393,111 votes against, while the other eight nominees each received between 2,473,998 and 22,097,928 votes against. Shareholder support was more mixed on executive pay matters. The advisory vote on named executive officer compensation (Proposal 7) received 403,157,465 votes for and 36,842,162 against, and the U.K. directors' remuneration policy (Proposal 10) received 398,711,622 for and 41,343,662 against. The filing does not state the outcome of each proposal beyond the vote tallies themselves, so investors should review the proxy statement for the proposals' full terms.

Royalty Pharma 8-K Report, Financial Results (May 8, 2025)

Royalty Pharma plc reported first-quarter 2025 results for the quarter ended March 31, 2025, with Portfolio Receipts up 17% to $839 million and Royalty Receipts up 12% to $788 million. Growth was driven mainly by the cystic fibrosis franchise, Trelegy and Xtandi, plus royalties from the 2024 launch of Voranigo and a $27 million Airsupra milestone. Net cash provided by operating activities was $596 million, down from $665 million a year earlier, reflecting higher interest paid and a $33 million one-time management fee tied to the MorphoSys Development Funding Bonds sale. Adjusted EBITDA rose 12% to $738 million and Portfolio Cash Flow rose 5% to $611 million. Net income attributable to Royalty Pharma plc was $238 million. Capital allocation was active. The company repurchased about 23 million Class A ordinary shares for $723 million under a new $3.0 billion authorization, and it raised full-year 2025 Portfolio Receipts guidance to $2,975 million to $3,125 million, up from $2,900 million to $3,050 million. It also entered a Biogen R&D funding arrangement for litifilimab worth up to $250 million over six quarters, and it increased its quarterly dividend by approximately 5%. Cash and cash equivalents were $1.1 billion and total debt principal was $7.8 billion at March 31, 2025. The internalization of its external manager, RP Management, LLC, is expected to close in the second quarter of 2025, following a shareholder meeting on May 12, 2025. The total transaction value is approximately $1.1 billion, consisting of about 24.5 million shares vesting over five to nine years, about $100 million in cash, and the assumption of $380 million of the Manager's debt. The company expects cash savings of greater than $100 million in 2026, rising to greater than $175 million in 2030. Guidance for operating and professional costs and interest paid will be updated after the closing.

Royalty Pharma Quarterly Report for Q1 Ended Mar 31, 2025

Royalty Pharma plc's first-quarter 2025 results show consolidated net income of $433.4 million, compared with a net loss of $4.3 million in the first quarter of 2024, driven mainly by a $127.1 million provision for changes in expected cash flows from financial royalty assets (provision income) versus $583.6 million of provision expense a year earlier. Net income attributable to Royalty Pharma plc was $238.3 million, or $0.55 per diluted Class A share, compared with $4.8 million, or $0.01, in the prior-year quarter. Total income and other revenues were essentially flat at $568.2 million, and Portfolio Receipts rose 17.1% to $839.3 million, with Royalty Receipts up 11.9% to $788.3 million. Management notes that the GAAP results are volatile because of non-cash provision accounting and emphasizes Portfolio Receipts and Portfolio Cash Flow as the primary operating measures. Capital deployment and shareholder returns were significant this quarter. The company repurchased 22.7 million Class A shares for about $723.1 million, paid $95.4 million in dividends ($0.22 per share), and sold the MorphoSys Development Funding Bonds in January 2025 for approximately $511 million. Cash and cash equivalents rose to $1.09 billion, and total shareholders' equity fell to $9.79 billion from $10.34 billion. Long-term debt, including current portion, totaled about $7.6 billion, against $7.8 billion of senior unsecured notes principal. Operating and personnel payments to the Manager were $89.8 million for the quarter. The pending Internalization, in which the company agreed in January 2025 to acquire its Manager for approximately $1.1 billion, is expected to close in the second quarter of 2025 subject to shareholder approval. The filing also notes that in May 2025 the company paid a $200 million regulatory milestone tied to the FDA approval of a new manufacturing hub for Adstiladrin, and that the Cytokinetics tranche four funding of $75 million was completed in April 2025.

Royalty Pharma 8-K Report, Material Agreement (Apr 11, 2025)

On April 11, 2025, Royalty Pharma plc filed a Form 8-K disclosing Amendment No. 1 to the Membership Interests Purchase Agreement previously announced on January 10, 2025. Under the original agreement, Royalty Pharma Holdings Ltd. (RPH), a subsidiary of Royalty Pharma plc, will acquire all equity interests of Royalty Pharma Manager, LLC (formerly Royalty Pharma, LLC) and RP Management, LLC from the named Sellers. The Transaction is subject to shareholder approval, and the company states it will file a proxy statement on Schedule 14A seeking that approval. Amendment No. 1, entered into by RPH, Royalty Pharma plc and Pablo Legorreta as Seller Representative, makes the parent company a party to the Purchase Agreement. At closing, each Seller will subscribe for Class B ordinary shares of Royalty Pharma plc equal in number to the non-voting Class E ordinary shares of RPH they receive as consideration. The Class B shares are issued at their nominal value of US$0.000001 each, payable in cash at closing. The filing is largely procedural. It sets out the structure for how Sellers will receive equity in the combined group but does not state the aggregate purchase price, valuation, or expected financial effects. Investors should review the forthcoming proxy statement for those details, along with the directors' and executive officers' interests described in the solicitation disclosures.

Royalty Pharma 8-K Report, Executive Changes (Apr 10, 2025)

Royalty Pharma plc (Nasdaq: RPRX) filed a Form 8-K dated April 10, 2025 to report the appointment of Dr. Vlad Coric to its Board of Directors, effective April 7, 2025. Dr. Coric will stand for election for the first time at the 2025 Annual General Meeting and Special Meeting of Shareholders, and is expected to join the Management Development and Compensation Committee after that meeting if elected. The Board has determined that he meets applicable independence standards under Nasdaq Global Select Market rules and Item 407(a) of Regulation S-K. He will receive compensation under the Company's Independent Director Compensation Policy, as described in the preliminary proxy statement filed February 13, 2025, and will enter into a standard deed of indemnity. The filing also attaches a press release dated April 8, 2025 announcing the appointment. That release describes Dr. Coric as Chairman and CEO of Biohaven, credits him with leading Biohaven through the FDA approval and launch of Nurtec ODT, and notes that Biohaven was sold to Pfizer in May 2022 for approximately $13 billion in total consideration. The release also states that Biohaven has completed multiple royalty transactions with Royalty Pharma. The filing additionally includes standard legal language referencing a pending Transaction, described as subject to shareholder approval and requiring a Schedule 14A proxy statement. The filing does not describe the Transaction's terms in detail beyond its stated expected benefits.

Royalty Pharma Annual Report, Year Ended Dec 31, 2024

Royalty Pharma plc (RPRX) reports that it is the largest buyer of biopharmaceutical royalties. In 2024 it generated Portfolio Receipts of $2.8 billion (versus $3.05 billion in 2023, a decline of $247.3 million, or 8.1%), driven by the absence of the $475.0 million Zavzpret milestone received in 2023. Royalty Receipts rose 13.1% to $2.77 billion, led by the cystic fibrosis franchise ($856.8 million), Trelegy ($283.7 million) and Evrysdi ($173.5 million). The company deployed $2.8 billion of capital in 2024, paid $376.5 million in dividends and repurchased $229.9 million of Class A shares. Consolidated net income was $1.33 billion, and net income attributable to Royalty Pharma plc was $858.98 million, down from $1.13 billion in 2023, largely reflecting a $732.5 million provision for changes in expected cash flows and expected credit losses. At year-end 2024, senior unsecured notes totaled $7.8 billion in principal, with $1.8 billion of revolving commitments available, and cash and cash equivalents were $929.0 million. Operating cash flow was $2.77 billion. The company is externally managed, and in January 2025 it agreed to acquire its Manager, RP Management, LLC, for approximately $1.1 billion, subject to shareholder approval and expected to close in the second quarter of 2025. The filing also flags risks including concentration (the top five franchises were 64% of Royalty Receipts), the accounting volatility of financial royalty assets, the Investment Company Act exemption, and tax treaty and Pillar Two developments.

Royalty Pharma 8-K Report, Financial Results (Feb 11, 2025)

Royalty Pharma plc (Nasdaq: RPRX) reported fourth-quarter and full-year 2024 results in a press release furnished as Exhibit 99.1 to this Form 8-K dated February 11, 2025. Royalty Receipts grew 12% to $729 million in Q4 2024 and 13% to $2,771 million for full year 2024, while Portfolio Receipts were $742 million in Q4 (up 1%) and $2,801 million for the full year (down 8% from $3,049 million, largely reflecting $525 million in Biohaven-related milestone payments received in 2023). Net cash provided by operating activities was $743 million in Q4 and $2,769 million for the full year, and Portfolio Cash Flow (non-GAAP) was $2,452 million for 2024, down 9%. The company deployed $2.8 billion of capital in 2024, announced $925 million of synthetic royalty transactions, and ended the year with $929 million of cash and total debt with principal value of $7.8 billion. For 2025, the company guided Portfolio Receipts of $2,900 million to $3,050 million, excluding future transactions, representing expected growth of 4% to 9%. In January 2025 the Board authorized a new share repurchase program of up to $3.0 billion, of which the company intends to repurchase $2.0 billion in 2025 subject to market conditions, replacing the unused $465 million under its prior program. The company also agreed to acquire its external manager, RP Management, LLC, in a transaction valued at approximately $1.1 billion, expected to generate cash savings of greater than $100 million in 2026 and close in the second quarter of 2025 subject to shareholder approval.

Royalty Pharma 8-K Report, Regulation FD Disclosure (Jan 13, 2025)

On January 13, 2025, Royalty Pharma plc furnished an investor presentation under Item 7.01 (Regulation FD) in connection with its participation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation provides a corporate update centered on 2024 results and a proposed internalization of its external manager. The company states that 2024 Portfolio Receipts are expected to be about $2.8 billion, at the high end of prior guidance of $2.75 billion to $2.8 billion, with 2024 Royalty Receipts growth expected to be about 13%. It also reports eight transactions executed in 2024 for $2.8 billion and the addition of royalties on eight new therapies. The most significant item for investors is the agreement to acquire RP Management, LLC, its external manager, for approximately $1.1 billion in total consideration. This consists of about $100 million in cash, $380 million of assumed manager debt (described as leverage neutral to Royalty Pharma), and about 24.5 million shares vesting over 5 to 9 years. The company expects cumulative 10-year cash savings of more than $1.6 billion, with annual savings of more than $175 million by 2030, and the transaction is estimated to close in the second quarter of 2025. The presentation also announces a new $3 billion share repurchase authorization, with an intent to repurchase $2 billion of shares in 2025 subject to market conditions. The filing is furnished rather than filed, and it references a separate Form 8-K filed January 10, 2025 for the transaction terms. Forward-looking statements, including the expected benefits of the internalization, are subject to shareholder approval of the transaction.

Royalty Pharma 8-K Report, Material Agreement (Jan 10, 2025)

On January 10, 2025, Royalty Pharma plc disclosed that its subsidiary, Royalty Pharma Holdings Ltd. (RPH), entered into a Membership Interests Purchase Agreement to acquire all equity interests in Royalty Pharma, LLC and RP Management, LLC, the external manager that conducts all of the company's business and operations. Consideration consists of $200 million in cash, less 2025 management fee payments received by the manager from January 1, 2025 through closing, plus 24,530,266 non-voting RPH shares. RPH will also assume RP Management's $380 million term loan facility. The Share Consideration to Pablo Legorreta vests straight-line over five years, and the other management members' shares vest over nine years. The company's press release estimates total transaction value of approximately $1.1 billion based on a $26.20 share price on January 8, 2025, and expects cumulative cash savings of more than $1.6 billion over ten years, with annual savings above $100 million in 2026 and above $175 million in 2030. The transaction is expected to close in the second quarter of 2025, requires shareholder approval, and can be terminated if not consummated by August 1, 2025. Voting agreements covering approximately 25% of fully diluted shares have been signed by board and senior management members. The same day, the board approved a new $3 billion share repurchase program that replaces the unused $465 million of the March 2023 $1 billion program. Management intends to repurchase $2 billion of shares in 2025, subject to market conditions, with the total depending on the discount to intrinsic value. The company stated that capital deployment guidance of $2.0 to $2.5 billion per year, its dividend growth commitment of mid-single digit percentages annually, and its investment grade credit rating commitment are unchanged. The filing also furnishes a press release, an investor presentation, and a transcript of the investor call. Management stated that the Share Consideration represents approximately 4% of shares outstanding, assuming all shares vest, and that the management fee currently paid to the manager is 6.5% of Portfolio Receipts plus 0.25% of the value of security investments.

Royalty Pharma 8-K Report, Financial Results (Jan 10, 2025)

Royalty Pharma plc furnished a press release on January 10, 2025, ahead of the 43rd Annual J.P. Morgan Healthcare Conference, giving a preliminary, unaudited update on its 2024 results. The company expects full-year 2024 Portfolio Receipts of approximately $2,800 million, at the upper end of its previous guidance range of $2,750 million to $2,800 million. It cites anticipated underlying growth of approximately 13% year-over-year in Royalty Receipts, its recurring cash inflows. Preliminary full-year 2024 figures are Adjusted EBITDA (non-GAAP) of approximately $2,560 million to $2,570 million, Portfolio Cash Flow (non-GAAP) of approximately $2,450 million to $2,455 million, and net cash provided by operating activities of approximately $2,760 million to $2,770 million. The filing states these figures remain subject to change as final adjustments and the audit are completed. Management reported approximately $2.8 billion of royalty transaction deployment in 2024, including a record year for synthetic royalty deals totaling $925 million, and cited announced transactions of approximately $15.5 billion since 2020. The development-stage pipeline covers over 40 projects, and the late-stage pipeline is described as having un-risk-adjusted peak sales in excess of $21 billion per year, which could translate to a potential of $1.2 billion annually in new royalties to the company. Key upcoming catalysts named include the aficamten PDUFA target action date of September 26, 2025, and pelacarsen Phase 3 topline results expected in 2025. The release also states that the company announced the acquisition of its external manager and a substantial increase in its share repurchase commitment.

Royalty Pharma 8-K Report, Material Agreement (Dec 31, 2024)

On December 31, 2024, Royalty Pharma plc (RPRX) filed a Current Report on Form 8-K disclosing two related corporate actions tied to a restructuring of RPI EPA Holdings, LP (the "Restructuring"). The Company entered into an amended Exchange Agreement with Royalty Pharma Holdings Limited ("RP Holdings"), several RPI partnership entities, and RPI EPA Vehicle LLC in connection with the Restructuring. The filing states that the full text of the Exchange Agreement is filed as Exhibit 10.1 and incorporated by reference. Separately, on the same date, the articles of association of RP Holdings were amended and restated in their entirety in connection with the Restructuring, as described in Exhibit 3.1. The filing identifies these as the only disclosed items, under Item 1.01 (Entry into a Material Definitive Agreement) and Item 5.03 (Amendments to Articles of Incorporation or Bylaws). The filing does not state the financial terms, economic impact, or rationale of the Restructuring. The report was signed by Terrance Coyne, Chief Financial Officer. For investors, the key takeaway is that the filing discloses a structural reorganization of an entity within the Company's group, but it does not provide quantitative detail on its effects.

Royalty Pharma 8-K Report, Financial Results (Nov 6, 2024)

Royalty Pharma plc (Nasdaq: RPRX) furnished an 8-K under Item 2.02 reporting results for the quarter ended September 30, 2024, via Exhibit 99.1. Portfolio Receipts rose 15% to $735 million, Royalty Receipts rose 15% to $732 million, and net cash provided by operating activities was $704 million, up 23%. Adjusted EBITDA (non-GAAP) was $679 million and Portfolio Cash Flow (non-GAAP) was $617 million, each up 17%. Capital Deployment was approximately $1.2 billion in the quarter and $2.2 billion for the first nine months, and the company reported cash and cash equivalents of $950 million and total debt with principal value of $7.8 billion at September 30, 2024. Management raised full-year 2024 Portfolio Receipts guidance to $2,750 million to $2,800 million, from $2,700 million to $2,775 million previously, with Royalty Receipts growth now expected at 11% to 13%, versus 9% to 12% before. The guidance excludes transactions announced after the release date. The company also repurchased approximately three million Class A ordinary shares for $95 million in the quarter, and stated 2024 interest paid is anticipated at about $160 million with approximately $260 million expected in 2025. During the quarter the company added royalties on several therapies, including synthetic royalties on Niktimvo and Yorvipath and a royalty on deucrictibant in Phase 3 development. Management cited FDA approvals for Cobenfy, Tremfya for ulcerative colitis and Voranigo during the period. Net income attributable to Royalty Pharma plc was $544 million, compared with $72 million a year earlier, and the filing includes an Adjusted EBITDA and Portfolio Cash Flow reconciliation to GAAP.

Royalty Pharma Quarterly Report for Q3 Ended Sep 30, 2024

Royalty Pharma plc (RPRX) reported third-quarter 2024 net income attributable to Royalty Pharma plc of $543,987 thousand ($1.22 basic EPS), compared with $72,114 thousand ($0.16) in the third quarter of 2023. Consolidated net income before tax was $806,358 thousand versus $122,077 thousand a year earlier. The quarter's results were lifted by a $227.6 million provision for changes in expected cash flows (income, versus $277.1 million of expense in Q3 2023) and by $127.4 million of other income, primarily gains on available-for-sale debt securities and equity securities. Total income and other revenues rose 5.3% to $564.7 million in the quarter, while income from financial royalty assets was $533.2 million for the quarter and $1.59 billion for the first nine months, down from $1.67 billion a year earlier, largely because of a non-recurring $475.0 million Zavzpret milestone in the first quarter of 2023. Portfolio Receipts were $734.6 million in the third quarter, up 15.3%, and $2.06 billion for the first nine months, down 10.9% from $2.31 billion, reflecting the prior-year milestone. Cash from operating activities for the first nine months was $2.03 billion. The company invested $2.2 billion in royalties, milestones and other contractual receipts in the first nine months, and in November 2024 it acquired a Niktimvo royalty for a $350 million upfront payment. Total debt principal was $7.8 billion at September 30, 2024, after the June 2024 issuance of $1.5 billion of senior unsecured notes, and cash and cash equivalents were $950.1 million. Shareholders received $282.8 million in dividends ($0.21 per Class A share in each of three quarterly payments) during the first nine months, and the company repurchased 6.6 million Class A shares for about $179.7 million, with $515.6 million remaining under the $1.0 billion authorization. Vertex accounted for 36% of total income and other revenues in the third quarter of 2024 (41% in the prior-year quarter).

Royalty Pharma 8-K Report, Regulation FD Disclosure (Sep 27, 2024)

On September 27, 2024, Royalty Pharma plc filed a Form 8-K under Item 7.01 (Regulation FD Disclosure) to disclose a regulatory milestone tied to its March 2023 royalty agreement with PureTech Health plc. On September 26, 2024, Bristol Myers Squibb announced that the U.S. Food and Drug Administration approved a New Drug Application for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults. BMS intends to market the drug as Cobenfy. Under the 2023 agreement, Royalty Pharma paid $100 million upfront, with up to $400 million in additional payments contingent on certain regulatory and commercial milestones, in exchange for a 3% royalty on sales up to $2 billion annually, after which the royalty drops to 1%. As a result of this approval, Royalty Pharma will pay PureTech a $25 million milestone payment. The filing is a short Regulation FD disclosure and includes standard forward-looking statement cautions. It does not provide Royalty Pharma's own financial results or updated guidance.

Royalty Pharma 8-K Report, Financial Results (Aug 8, 2024)

Royalty Pharma plc (Nasdaq: RPRX) reported second quarter 2024 results on August 8, 2024, as furnished in Exhibit 99.1 press release. Portfolio Receipts rose 12% to $608 million, and Royalty Receipts grew 11% to $605 million, driven by the cystic fibrosis franchise, Trelegy, Tremfya and incremental Evrysdi royalties. Net cash provided by operating activities was $658 million, Adjusted EBITDA (non-GAAP) was $560 million, and Portfolio Cash Flow (non-GAAP) was $574 million. The company raised its full-year 2024 Portfolio Receipts guidance to $2,700 million to $2,775 million, from $2,600 million to $2,700 million previously. The guidance excludes contributions from transactions announced after the release date and includes expected Royalty Receipts growth of 9% to 12%. Capital Deployment was $951 million in the quarter, and the company said it announced new transactions of up to approximately $2.0 billion in the quarter, including the Voranigo royalty acquisition from Agios for an upfront payment of $905 million, which will be paid following FDA approval. Balance sheet activity included issuance of $1.5 billion of senior unsecured notes at a weighted average coupon of 5.5%. As of June 30, 2024, cash and cash equivalents were $1.8 billion and total debt principal was $7.8 billion, with a weighted-average cost of debt of 3.1%. The company repurchased about three million Class A ordinary shares for $84 million in the quarter.

Royalty Pharma Quarterly Report for Q2 Ended Jun 30, 2024

Royalty Pharma plc (RPRX) reported second-quarter 2024 results for the three months ended June 30, 2024, with total income and other revenues of $537.3 million, roughly flat versus $538.2 million a year earlier. Net income attributable to Royalty Pharma plc was $102.0 million, or $0.23 per diluted Class A share, compared with $227.6 million, or $0.50, in the second quarter of 2023. The decline was driven mainly by a $212.4 million provision for changes in expected cash flows and credit losses, and by a $47.1 million loss on equity securities. For the first six months, net income attributable to Royalty Pharma plc was $106.8 million, down from $568.4 million, largely because the prior-year period included a $475.0 million Zavzpret milestone payment and non-recurring interest income. Cash position and funding strengthened during the period. Cash and cash equivalents rose to $1.76 billion at June 30, 2024, from $477.0 million at year-end 2023, after the company issued $1.5 billion of senior unsecured notes in June 2024 and generated $1.32 billion of operating cash flow in the first half. Total long-term debt was $7.60 billion carrying value against $7.8 billion of principal. The company spent $814.7 million on acquisitions of financial royalty assets in the first six months and expanded its Cytokinetics funding collaboration, with up to $575 million in commitments. The filing also highlights Portfolio Receipts of $608.0 million in the quarter, up 11.6% from $544.6 million, and Vertex's cystic fibrosis franchise as the largest royalty source, at 36% of second-quarter total income and other revenues. Subsequent to quarter end, the filing notes FDA approval of Voranigo, for which the company agreed to pay $905 million upfront.

Royalty Pharma 8-K Report, Regulation FD Disclosure (Aug 7, 2024)

Royalty Pharma plc reported in this Form 8-K, filed August 7, 2024 under Item 7.01 (Regulation FD Disclosure), that the U.S. Food and Drug Administration approved a New Drug Application for Voranigo (vorasidenib) on August 6, 2024, as announced by Servier. Voranigo is described as a first-in-class targeted therapy for patients with isocitrate dehydrogenase 1 and 2 (IDH1/2) mutant diffuse glioma. Under the May 2024 royalty agreement with Agios Pharmaceuticals, Royalty Pharma agreed to pay $905 million to Agios upon FDA approval of Voranigo. In exchange, Royalty Pharma receives a 15% royalty on annual U.S. net sales of Voranigo up to $1 billion and a 12% royalty on annual U.S. net sales above $1 billion. Royalty Pharma projects peak annual sales potential greater than $1 billion for Voranigo, which it expects to generate royalties greater than $150 million annually to the Company. The Company anticipates royalties from Voranigo through 2038.

Royalty Pharma 8-K Report, Corporate Update (Jun 20, 2024)

On June 17, 2024, PTC Therapeutics, Inc. exercised an option to sell half of its retained royalties on Roche's Evrysdi to a subsidiary of Royalty Pharma plc for approximately $242 million upfront. The filing states that this option arose from the Evrysdi royalty transaction with PTC announced in October 2023. Evrysdi, an oral SMN2 splicing modifier for spinal muscular atrophy approved by the FDA in 2020, generated sales of approximately CHF 1.4 billion ($1.6 billion) in 2023, an increase of 39% at constant exchange rates. After the transaction, Royalty Pharma's ownership of the Evrysdi royalty rises from 81% to 90.5% (before the cap), equating to a royalty of 7.2% to 14.5% on worldwide net product sales, not including any future PTC option exercises. Royalty Pharma will receive the increased share starting with royalties paid on sales for the second quarter of 2024. The total funding across its Evrysdi royalty transactions is $1.9 billion upfront, including up to $250 million for an option. PTC retains the option, exercisable until December 31, 2025, to sell its remaining 9.5% of the Evrysdi royalty to Royalty Pharma for $250 million less royalties received. The filing estimates the duration of the royalty stream at 2030-2035 for the 2020 deal and 2035-2036 for the later transactions.

Royalty Pharma 8-K Report, Material Agreement (Jun 10, 2024)

Royalty Pharma plc filed this Form 8-K to report that on June 10, 2024 it closed its previously announced offering of three series of senior notes, totaling $1.5 billion: $500 million of 5.150% Senior Notes due 2029, $500 million of 5.400% Senior Notes due 2034, and $500 million of 5.900% Senior Notes due 2054. The Notes were issued under a base indenture dated September 2, 2020, as supplemented by a Third Supplemental Indenture dated June 10, 2024, among the company, Royalty Pharma Holdings Ltd (the guarantor) and Wilmington Trust, National Association, as trustee. The Notes are senior unsecured obligations guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd. Interest is fixed at the stated rates and payable semi-annually on March 2 and September 2, beginning March 2, 2025, with maturities on September 2 of 2029, 2034 and 2054. The Indenture contains customary covenants and requires the issuer to offer to repurchase the Notes upon certain change of control events, and the company may redeem the Notes under terms set out in the Indenture. For investors, the filing is primarily a debt financing disclosure that adds $1.5 billion of fixed-rate senior unsecured obligations across three maturities. The filing itself does not describe the use of proceeds. The full terms are in the exhibits, including the Base Indenture and Third Supplemental Indenture, and legal opinions from Davis Polk & Wardwell LLP.

Royalty Pharma 8-K Report, Shareholder Vote Results (Jun 6, 2024)

Royalty Pharma plc held its annual general meeting of shareholders on June 6, 2024, with 510,790,642 Class A and Class B ordinary shares present or represented by proxy, representing 85.49% of the combined voting power entitled to vote. That constituted a quorum. Shareholders voted on ten proposals described in the company's April 25, 2024 proxy statement. Shareholders elected all eight director nominees to serve until the 2025 annual general meeting. Each nominee received more votes For than Against, with the lowest For count being 457,219,827 for Ted Love, M.D., who also had the highest Against count at 28,488,315. Shareholders also approved, on a non-binding advisory basis, the compensation of the named executive officers (448,091,225 For, 37,716,521 Against), and ratified Ernst & Young LLP as the independent registered public accounting firm (510,538,774 For, 175,866 Against). The meeting also covered U.K.-specific matters. Shareholders approved receipt of the U.K. Annual Report and Accounts for the fiscal year ended December 31, 2023, the U.K. directors' remuneration policy, and the U.K. directors' remuneration report on an advisory basis. They re-appointed Ernst & Young Chartered Accountants as U.K. statutory auditor, authorized the Board to set the auditor's remuneration, and approved two share allotment authorizations, one of which permits allotments without pre-emption rights.

Royalty Pharma 8-K Report, Material Agreement (Jun 4, 2024)

Royalty Pharma plc (RPRX) filed a Current Report on Form 8-K reporting that on June 3, 2024 it entered into an underwriting agreement for a registered public offering of senior notes. The Issuer, Royalty Pharma plc, agreed to issue and sell $500 million aggregate principal amount each of its 5.150% Senior Notes due 2029, 5.400% Senior Notes due 2034, and 5.900% Senior Notes due 2059, totaling $1.5 billion in principal. The offering is being made under an effective Form S-3 shelf registration statement (Registration File No. 333-279905). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd, the Guarantor named in the agreement. The underwriters are BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and TD Securities (USA) LLC, acting as representatives of the several underwriters. The offering is expected to close on June 10, 2024, subject to customary closing conditions. The filing is limited to this debt issuance and its related exhibits: the Underwriting Agreement (Exhibit 1.1) and the cover page Interactive Data File (Exhibit 104). It does not contain financial results or other operating information.

Royalty Pharma 8-K Report, Corporate Update (May 29, 2024)

Royalty Pharma plc filed this Form 8-K under Item 8.01 (Other Events) to disclose that Johnson and Johnson announced positive results from the pivotal Phase 3 MDD3001 clinical trial of seltorexant. Seltorexant is described as a potential first-in-class selective antagonist of the human orexin-2 receptor, being studied as an adjunctive treatment to baseline antidepressants in adult and elderly patients with major depressive disorder (MDD) with insomnia symptoms. According to the filing, the study met all primary and secondary endpoints and was safe and well-tolerated. The filing notes that there are currently no approved therapies to treat MDD with insomnia symptoms, and that the findings will be presented at this year's American Society of Clinical Psychopharmacology Annual Meeting. For Royalty Pharma, the filing states the company is entitled to a mid-single digit royalty on worldwide net sales of seltorexant. The filing also cites Johnson and Johnson's December 2023 Enterprise Business Review, in which the company stated that seltorexant has the potential for non-risk adjusted peak sales of between $1 billion and $5 billion. The filing is a disclosure of a third-party clinical milestone rather than a financial result for Royalty Pharma, and it includes no quantified financial impact on the company's own results. Investors should view it as a pipeline-related development affecting a royalty asset whose future value depends on commercialization and regulatory outcomes, which the filing does not address.

Royalty Pharma 8-K Report, Financial Results (May 9, 2024)

Royalty Pharma plc (Nasdaq: RPRX) reported first quarter 2024 results on May 9, 2024, as described in Exhibit 99.1 (press release) furnished under Item 2.02. Portfolio Receipts were $717 million, down 37% from $1,131 million in the prior-year quarter, reflecting a high comparison base: the first quarter of 2023 included a $475 million Zavzpret milestone payment and a $29 million Airsupra payment. Royalty Receipts grew 14% to $705 million, driven by Trelegy, the cystic fibrosis franchise and incremental Evrysdi royalties acquired in October 2023. Net cash provided by operating activities was $665 million, versus $1,034 million a year earlier, and Adjusted EBITDA (non-GAAP) was $656 million. Portfolio Cash Flow (non-GAAP) was $584 million. Management confirmed full-year 2024 guidance, with Portfolio Receipts expected at $2,600 million to $2,700 million, excluding future transactions. That guidance includes expected Royalty Receipts growth of 5% to 9%. The company also announced an agreement to acquire royalties and milestones on Sanofi's frexalimab from ImmuNext for approximately $525 million in cash including estimated transaction costs. Capital Deployment in the quarter was $93 million, and the company cited more than $3.5 billion of financial capacity including cash and leverage. Cash and cash equivalents were $843 million and total debt principal was $6.3 billion as of March 31, 2024. The filing also highlights a development-stage portfolio of 15 therapies, 11 of which are in Phase 3 development or under regulatory review. Key expected events over the next year include FDA filings for aficamten and pelabresib, pivotal results for seltorexant and Tremfya in Crohn's disease, and an FDA action date for KarXT. The release states a commitment to grow the dividend by a mid-single-digit percentage annually.

Royalty Pharma Quarterly Report for Q1 Ended Mar 31, 2024

Royalty Pharma plc's first-quarter 2024 results show a sharp drop in profitability driven by a non-cash provision for changes in expected cash flows from financial royalty assets. Total income and other revenues were $567,978 thousand (about $568.0 million) versus $683,971 thousand in the first quarter of 2023, a decrease of $115,993 thousand (17.0%). The company recorded a provision for changes in expected cash flows of $583,600 thousand, against $118,804 thousand a year earlier, primarily related to the cystic fibrosis franchise and Crysvita. As a result, the company reported an operating loss of $73,774 thousand and net income attributable to Royalty Pharma plc of $4,778 thousand, or $0.01 per diluted Class A share, compared with $340,755 thousand, or $0.76 per share, in the prior-year quarter. The prior-year quarter included a non-recurring $475.0 million Zavzpret milestone payment. Cash generation remained substantial even as GAAP earnings fell. Net cash provided by operating activities was $664,638 thousand, compared with $1,033,837 thousand in the first quarter of 2023. Portfolio Receipts were $716,997 thousand versus $1,131,033 thousand, and Adjusted EBITDA (non-GAAP) was $656,476 thousand. Cash and cash equivalents rose to $843,000 thousand at March 31, 2024, from $477,010 thousand at December 31, 2023. The company paid a quarterly dividend of $0.21 per Class A share totaling $93.8 million, invested $93 million in royalties, milestones and other contractual receipts during the quarter, and did not repurchase any shares. Senior unsecured notes totaled $6.3 billion in par value, and the company had $1.8 billion of revolving commitments available. Subsequent to quarter end, the company announced it would acquire royalties and milestones on frexalimab from ImmuNext, Inc. for approximately $525 million including estimated transaction costs. The filing also notes that the company's accounting model for financial royalty assets can produce volatile and unpredictable GAAP results, and that the company will consider Portfolio Receipts as its key operating performance measure.

Royalty Pharma Annual Report, Year Ended Dec 31, 2023

Royalty Pharma plc's 2023 Form 10-K reports Portfolio Receipts of $3.05 billion, up from $2.79 billion in 2022, with royalty receipts of $2.45 billion and milestones and other contractual receipts of $599.3 million. The company describes itself as the largest buyer of biopharmaceutical royalties and deployed $2.2 billion of cash in 2023 to acquire royalties, milestones and other contractual receipts. Net income attributable to Royalty Pharma plc rose to $1.13 billion in 2023 from $42.8 million in 2022, driven largely by the absence of 2022's $615.8 million financial royalty asset impairment and a $366.2 million other income, net line item that included $230.8 million of gains on available for sale debt securities. Operating income was $1.49 billion versus $307.1 million a year earlier. Cash generation and shareholder returns were strong. Net cash provided by operating activities was $2.99 billion, versus $2.14 billion in 2022, helped by a $475.0 million Zavzpret milestone. The company repaid $1.0 billion of senior unsecured notes in September 2023, paid $358.3 million in dividends ($0.20 per quarter), and repurchased Class A shares for $304.8 million. Total senior unsecured notes were $6.3 billion at year end, with $1.8 billion available under the revolving credit facility, and the company reported compliance with its financial covenants. Investors should note that reported GAAP results are volatile because most royalties are accounted for as financial assets under the effective interest method. The 2023 provision for changes in expected cash flows was $560.7 million expense, and the filing states that Vertex's cystic fibrosis franchise accounted for 36% of total income and other revenues. The filing also highlights concentration risk: the top five product franchises represented 66% of royalty receipts in 2023, and the company is externally managed by RP Management, LLC, with Operating and Personnel Payments set at 6.5% of Portfolio Receipts.

Royalty Pharma 8-K Report, Financial Results (Feb 15, 2024)

Royalty Pharma plc (Nasdaq: RPRX) reported fourth quarter and full year 2023 results on February 15, 2024, as furnished in Exhibit 99.1, a press release. Portfolio Receipts, now the company's key performance metric, were $736 million in Q4 2023, down 31% from the prior year period because of accelerated Biohaven payments received in Q4 2022. For full year 2023, Portfolio Receipts rose 9% to $3,049 million, driven by strong portfolio performance and new royalty acquisitions. Net cash provided by operating activities was $773 million in Q4 and $2,988 million for the full year, and Adjusted EBITDA was $2,806 million for 2023. Royalty receipts grew 10% in the quarter and 8% for the year. The company announced new transactions of up to $4.0 billion in 2023 and reported Capital Deployment of $2.2 billion for the year. Cash and cash equivalents were $477 million and total debt principal was $6.3 billion at December 31, 2023. The company also repurchased about 10 million shares for $305 million in 2023 under its $1.0 billion program. Management guided 2024 Portfolio Receipts to $2,600 million to $2,700 million, including expected royalty receipts growth of 5% to 9%, excluding future transactions. For investors, the key takeaways are the year-over-year growth in royalty receipts and the 2024 guidance, which excludes transactions announced after the release date. The Q4 decline in headline receipts reflects a one-time item in the prior year rather than a deterioration in the royalty base. Interest paid is expected to be about $160 million in 2024.

Royalty Pharma 8-K Report, Corporate Update (Feb 6, 2024)

Royalty Pharma plc (RPRX) filed this Form 8-K under Item 8.01 (Other Events) to disclose its financial exposure to MorphoSys AG following an agreement announced February 5, 2024, under which Novartis would acquire MorphoSys for €68 per share. Royalty Pharma's July 2021 strategic funding partnership with MorphoSys committed up to $2.025 billion to enable MorphoSys's acquisition of Constellation Pharmaceuticals, in exchange for royalties, development funding bonds and equity. Royalty Pharma holds royalties on four therapies: a 3% royalty on future net sales of pelabresib (myelofibrosis, with an NDA expected mid-2024 based on the phase 3 MANIFEST-2 study), a 3% royalty on tulmimetostat (phase 2 EZH2 inhibitor), a tiered mid-single digit royalty on Tremfya (marketed by Johnson and Johnson, which generated $3.1 billion in 2023 sales), and a tiered 3.3% to 4.2% effective royalty on trontinemab (Alzheimer's, in development by Roche). The company provided $300 million in exchange for Development Funding Bonds, which MorphoSys will repay through 36 consecutive payments totaling approximately $660 million (2.2 times the funded amount), beginning in the fourth quarter of 2024. Royalty Pharma also acquired 1,337,552 MorphoSys shares, which the filing states would be worth approximately $100 million at the proposed Novartis acquisition price and current exchange rates. The acquisition would therefore likely accelerate realization of Royalty Pharma's MorphoSys-related investments, though the filing does not state the timing or terms of any such payoff.

Royalty Pharma 8-K Report, Financial Results (Jan 8, 2024)

Royalty Pharma plc (Nasdaq: RPRX) furnished an 8-K on January 8, 2024 disclosing a preliminary, unaudited update on its fiscal 2023 results, issued via a press release (Exhibit 99.1) ahead of the 42nd Annual J.P. Morgan Healthcare Conference. The company expects full-year 2023 Portfolio Receipts of approximately $3,050 million, which includes a $50 million payment related to oral zavegepant and exceeds the upper end of its previous guidance range of $2,950 million to $3,000 million. Management cites underlying growth of 11% year-over-year before Biohaven-related payments, and expects Net cash provided by operating activities of approximately $2,980 million to $2,990 million for 2023. The release also highlights capital deployment: announced transactions of approximately $13 billion since 2020, including $4.0 billion in 2023, and $775 million of synthetic royalty transactions in 2023, the company's strongest year for that category. Management states that investments made since 2020 are estimated to add approximately $1.2 billion to Portfolio Receipts in 2025 based on consensus sales forecasts. The company also reiterated a capital deployment target of $10 billion to $12 billion for 2022 through 2026. The company is renaming its Royalty Receipts metric as Portfolio Receipts, which it says yields the same total as the former Adjusted Cash Receipts while presenting royalty receipts net of legacy non-controlling interests. Because the figures are preliminary and unaudited, they remain subject to change pending final adjustments and audit, and a full fourth-quarter and full-year 2023 results conference call is expected in February 2024.

Royalty Pharma 8-K Report, Material Agreement (Dec 27, 2023)

On December 22, 2023, Royalty Pharma plc and its consolidated subsidiary Royalty Pharma Holdings Ltd. entered into Amendment No. 3 to the Amended and Restated Revolving Credit Agreement with Bank of America, N.A., as Administrative Agent, and the other lenders. The amendment increases total borrowing capacity under the unsecured revolving credit facility from $1.5 billion to $1.8 billion. It also extends the maturity of $1.69 billion of the revolving commitments from October 31, 2027 to December 22, 2028, while the remaining $110 million continues to mature on October 31, 2027. The amendment also makes certain other technical modifications. The facility bears interest at either a base rate or Daily SOFR, the Alternative Currency Term Rate or the Alternative Currency Daily Rate, in each case plus an applicable margin. The credit agreement requires the company to keep a consolidated leverage ratio of funded debt to Adjusted EBITDA at or below 4.00 to 1.00, or at or below 4.50 to 1.00 following a qualifying material acquisition. It also requires a consolidated coverage ratio of Adjusted EBITDA to consolidated interest expense at or above 2.50 to 1.00. The agreement includes customary limits on additional indebtedness, dividends, certain payments, and the acquisition and disposition of assets. For investors, the filing reports a larger, longer-dated liquidity source under the revolver and sets out the financial maintenance covenants that govern it. The filing states that the full credit agreement is attached as Exhibit 10.1 and that the summary is qualified by reference to that document.